Get started
Author

Marta Nyakas

Observed names: M Nyakas, M. Nyakas, M.S. Nyakas, Nyakas, M, Nyakas, Marta, Nyakas, Marta; https://orcid.org/0000-0001-6331-3440
Observed institutions: Oslo University Hospital, Novartis (Switzerland), The University of Sydney, The University of Queensland, University of Oslo, Royal North Shore Hospital, Haukeland University Hospital, Princess Alexandra Hospital, Institut Jules Bordet, The Alfred Hospital, Westmead Hospital, University Hospital Zurich, St Olav's University Hospital, Istituto Oncologico Veneto, University Hospital Schleswig-Holstein, Melanoma Institute Australia, Essen University Hospital, Gallipoli Medical Research Foundation, Fondazione IRCCS Istituto Nazionale dei Tumori, Deutsches Konsortium für Translationale Krebsforschung, University of Bergen, University of Duisburg-Essen, Macquarie University
ORCID: 0000-0001-6331-3440
Observed ORCID: 0000-0001-6331-3440
OpenAlex ID: A5032262791
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
2012 · Keith T. Flaherty, Caroline Robert, et al. · New England Journal of Medicine · 2,160
PDF
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF -Mutated Melanoma
2017 · Georgina V. Long, Axel Hauschild, et al. · New England Journal of Medicine · 1,512
PDF
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
2017 · Paolo A Ascierto, Michele Del Vecchio, et al. · The Lancet Oncology · 509
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
2020 · Reinhard Dummer, Axel Hauschild, et al. · New England Journal of Medicine · 408
PDF
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
2013 · Einar Osland Vik-Mo, Marta Nyakas, et al. · Cancer Immunology Immunotherapy · 315
PDF
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma
2018 · Axel Hauschild, Reinhard Dummer, et al. · Journal of Clinical Oncology · 256
Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.
2017 · Paolo Antonio Ascierto, Ignacio Melero, et al. · Journal of Clinical Oncology · 238
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
2019 · Y.J.L. Jansen, E.A. Rozeman, et al. · Annals of Oncology · 226
PDF
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF -Mutant Melanoma
2017 · Jean-Pierre Delord, Caroline Robert, et al. · Clinical Cancer Research · 198
PDF
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
2013 · Caroline Robert, Reinhard Dummer, et al. · The Lancet Oncology · 169
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
2023 · Paolo Antonio Ascierto, Evan J. Lipson, et al. · Journal of Clinical Oncology · 166
PDF
Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
2011 · Paal Fr. Brunsvig, Jon Amund Kyte, et al. · Clinical Cancer Research · 159
Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations
2017 · P.A. Ascierto, P. Bono, et al. · Annals of Oncology · 150
PDF
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
2024 · Georgina V. Long, Axel Hauschild, et al. · New England Journal of Medicine · 144
Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study
2024 · G.V. Long, M.S. Carlino, et al. · Annals of Oncology · 126
PDF
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma
2023 · Caroline Robert, Matteo S. Carlino, et al. · Journal of Clinical Oncology · 116
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
2018 · Matteo S. Carlino, Georgina V. Long, et al. · European Journal of Cancer · 99
PDF
Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
2023 · Jani Huuhtanen, Henna Kasanen, et al. · Journal of Clinical Investigation · 98
PDF
BRAF mutational status as a prognostic marker for survival in malignant melanoma: a systematic review and meta-analysis
2020 · L. Ny, M. Hernberg, et al. · Acta Oncologica · 89
PDF
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
2021 · Andrew Bottomley, Corneel Coens, et al. · The Lancet Oncology · 73
PDF
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
2020 · Paolo Antonio Ascierto, Michele Del Vecchio, et al. · Journal for ImmunoTherapy of Cancer · 70
PDF
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
2020 · Prachi Bhave, Lalit Pallan, et al. · British Journal of Cancer · 64
PDF
Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti–PD-1–Resistant Advanced Melanoma
2022 · Alexander N. Shoushtari, Anthony J. Olszanski, et al. · Clinical Cancer Research · 62
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma
2020 · Igor Puzanov, Antoni Ribas, et al. · JAMA Oncology · 61
PDF
A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
2023 · S. Piperno-Neumann, M. S. Carlino, et al. · British Journal of Cancer · 60
PDF
Works count: 129
Citation count: 8,191
H-index: 34
I10-index: 45
Year
Topic
Type